GlaxoSmithKline agreed to buy an experimental hematologic cancer drug from a Chinese biotech company for up to 750 million US dollars to continue to enrich its expanding oncology pipeline. The British pharmaceutical company said in a statement on Tuesday that it will conduct multiple myeloma treatment tests on this drug purchased from the unlisted company Enmu Biotech and begin early clinical trials next year.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.